Related Experiment Video
Updated: Aug 6, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
New Combination Drug for Depression.
1Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .
Dextromethorphan-bupropion (Auvelity) is approved for major depressive disorder but carries risks. It may increase suicidal thoughts in young patients and cause seizures, with common side effects like dizziness and nausea.
Area of Science:
- Pharmacology
- Neuroscience
- Psychiatry
Background:
- Major Depressive Disorder (MDD) is a prevalent and debilitating mental health condition.
- Pharmacological interventions are crucial for managing MDD symptoms.
- Extended-release formulations aim to improve patient adherence and therapeutic outcomes.
Purpose of the Study:
- To summarize the approved use, safety profile, and adverse effects of dextromethorphan-bupropion for MDD treatment.
- To inform healthcare providers and patients about the potential risks associated with this antidepressant.
- To provide a concise overview of the drug's characteristics.
Main Methods:
- Review of FDA approval documentation and prescribing information.
- Analysis of clinical trial data regarding efficacy and safety.
- Synthesis of reported adverse events and warnings.
Main Results:
- Dextromethorphan-bupropion is approved for adult MDD.
- A "boxed warning" highlights increased risk of suicidal thoughts/behaviors in pediatric and young adult patients.
- Seizure risk is noted, particularly at higher doses.
Conclusions:
- Dextromethorphan-bupropion offers a new treatment option for MDD.
- Careful patient monitoring is essential due to potential serious adverse effects.
- Common side effects necessitate management strategies to support treatment adherence.
More Related Videos
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
05:19Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
Published on: July 7, 2023
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drug Therapy
Antianxiety Medications
Depression: Overview
Electroconvulsive Therapy